Поиск
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.

Список литературы

  1. Czaja CA, Scholes D, Hooton TM et al. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis 2007; №45:273–280.
  2. Gupta K, Hooton TM, Naber KG et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; №52:103–120.
  3. Prabhu A, Taylor P, Konecny P et al. Pyelonephritis: what are the present day causative organisms and antibiotic susceptibilities? Nephrology 2013; №18:463–467.
  4. Kim B, Myung R, Kim J et al. Descriptive Epidemiology of Acute Pyelonephritis in Korea, 2010-2014: Population-based Study. J Korean Med Sci. 2018; №33(49): e310.
  5. Kaprin A.D., Apolihin O.I., Sivkov A.V., Moskaleva N.G., Solnceva T.V., Komarova V.A. Analysis of urological and nephrological morbidity and mortality in the Russian Federation for 2003-2013. Jeksperimental’naja i klinicheskaja urologija. 2015; 2:4–12. Russian (Каприн А.Д., Аполихин О.И., Сивков А.В., Москалева Н.Г., Солнцева Т.В., Комарова В.А. Анализ уронефрологической заболеваемости и смертности в Российской Федерации за 2003- 2013 гг. Экспериментальная и клиническая урология. 2015; 2:4–12).
  6. М.И. Коган, Ю.Л. Набока, И.А. Гудима, С.К. Беджанян. Экспериментальное моделирование острого пиелонефрита. Урология 2016; №4: с.110-113.
  7. Конопля А.И., Братчиков О.И., Холименко И.М., Шатохин М.Н. и др. Состояние иммунного статуса у пациентов с серозной и гнойной формами острого пиелонефрита. Урология 2016; №2: с.10-16.
  8. Jeon DH, Jang HN, Cho HS, et al. Incidence, risk factors, and clinical outcomes of acute kidney injury associated with acute pyelonephritis in patients attending a tertiary care referral center. Ren Fail. 2019 Nov;41(1):204-210. doi: 10.1080/0886022X.2019.1591995.
  9. Talan DA, Takhar SS, Krishnadasan A, Abrahamian FM, Mower WR, Moran GJ. Fluoroquinolone-resistant and extended spectrum β-lactamase-producing Escherichia coli infections in patients with pyelonephritis, United States. Emerg Infect Dis 2016; 22:1594-603.
  10. van Nieuwkoop C, van der Starre WE, Stalenhoef JE, et al. Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo controlled non-inferiority trial in men and women. BMC Med 2017; 15:70
  11. Dae-Hong Jeon, Ha Nee Jang, Hyun Seop Cho et al. Incidence, risk factors, and clinical outcomes of acute kidney injury associated with acute pyelonephritis in patients attending a tertiary care referral center. Ren Fail. 2019 Nov;41(1):204-210. doi: 10.1080/0886022X.2019.1591995.
  12. Kim Y, Seo MR, Kim SJ, et al. Usefulness of blood cultures and radiologic imaging studies in the management of patients with community-acquired acute pyelonephritis. Infect Chemother 2017; 49:22-30.

  1. Scholes, D., et al. Risk factors associated with acute pyelonephritis in healthy women. Ann Intern Med 2005; №142 (1): 20-27. https://www.ncbi.nlm.nih.gov/pubmed/15630106
  2. Fulop, T. Acute Pyelonephritis Workup. 2017. http://emedicine.medscape.com/article/245559-workup
  3. Bonkat G., Pickard R., Bartoletti R. et al. EAU Guidelines on Urological Infections, 2018
  4. Bader, M.S., et al. Management of complicated urinary tract infections in the era of antimicrobial resistance. Postgrad Med 2010 (6); 122: 7-15. https://www.ncbi.nlm.nih.gov/pubmed/21084776
  5. Wagenlehner, F., et al. The Global Prevalence of Infections in Urology Study: A Long- Term, Worldwide Surveillance Study on Urological Infections. Pathogens 2016; №5 (1):10-8. https://www.ncbi.nlm.nih.gov/pubmed/26797640
  6. van Nieuwkoop, C., et al. Predicting the need for radiologic imaging in adults with febrile urinary tract infection. Clin Infect Dis 2010; 51(11): 1266-1272. https://www.ncbi.nlm.nih.gov/pubmed/21034195
  7. Cruz J, Figueiredo F, Matos AP et al. Infectious and Inflammatory Diseases of the Urinary Tract: Role of MR Imaging. Magn Reson Imaging Clin N Am. 2019; 27(1):59-75.
  8. Expert Panel on Urologic Imaging: Nikolaidis P, Dogra VS, Goldfarb S, Gore JL et al. ACR Appropriateness Criteria® Acute Pyelonephritis. J Am Coll Radiol. 2018 Nov;15(11S): 232- 239.
  9. Yagihashi Y, Shimabukuro S, Toyosato T, Arakaki Y. Can excretory phase computed tomography predict bacteremia in obstructive calculous pyelonephritis? Int Urol Nephrol. 2018; 50(12):2123-2129.
  10. Cattrall J W. S., Robinson AV., Kirby A. A systematic review of randomised clinical trials for oral antibiotic treatment of acute pyelonephritis. Eur J Clin Microbiol Infect Dis 2018; 37(12):2285-2291.
  11. Wagenlehner FM, Sobel JD, Newell P. Et al. Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. Clin Infect Dis. 2016; №63(6):754-762.
  12. Johnson J. R., Russo T. A. Acute Pyelonephritis in Adults. N Engl J Med 2018; №378:48- 59.
  13. Nosocomial and Health Care Associated Infections in Urology // Health Publication / K.G. Naber et al. (eds.). — Berlin, 2001. — 207 p.
  14. Bader MS, Loeb M, Brooks AA. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad Med. 2017 Mar;129(2):242-258. doi: 10.1080/00325481.2017.1246055
  15. Аляев Ю.Г., Аполихин О.И., Пушкарь Д.Ю., Козлов Р.С. и др. Федеральные клинические рекомендации Антимикробная терапия и профилактика инфекций почек, мочевыводящих путей и мужских половых органов - М., 2017.
  16. H-S Choe et al. Summary of the UAA-AAUS guidelines for urinary tract infections. International Journal of Urology (2018) 25, 175—185.
  17. Takahashi S, Kurimura Y, Takeyama K et al. Efficacy of treatment with carbapenems and third-generation cephalosporins for patients with febrile complicated pyelonephritis. J. Infect. Chemother. 2009; 15: 390–5.
  18. Jeon JH, Kim K, Han WD et al. Empirical use of ciprofloxacin for acute uncomplicated pyelonephritis caused by Escherichia coli in communities where the prevalence of fluoroquinolone resistance is high. Antimicrob. Agents Chemother. 2012; 56: 3043–6.
  19. Sandberg T, Skoog G, Hermansson AB et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non- inferiority trial. Lancet 2012; 380:484–90.
  20. Wyatt CM, et al. The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy. Kidney Int. 2009 Feb; 75(4): 428–434
  21. Забиров К.И., Максимов В.А., Борисик В.И., Яровой С.К. с соавт. Лечение урологических пациентов с ВИЧ инфекцией. Урология 2010; 2:6-10.
  22. Nicolle LE. Urinary tract infections in special populations: diabetes, renal transplant, HIV infection, and spinal cord injury. Infect. Dis. Clin. North Am. 2014; 28:91–104.
  23. Campbell MF, Wein AJ, Kavoussi LR. Campbell-Walsh Urology, 9th edn. Saunders, Philadelphia, PA, 2007.
  24. Borofsky MS, Walter D, Li H, et al. Institutional characteristics associated with receipt of emergency care for obstructive pyelonephritis at community hospitals. J Urol. 2015; 193(3):851-6.
  25. Nana GR, Brodie A, Akhter W., et al. Nephroureterectomy for emphysematous pyelonephritis: An aggressive approach is sometimes necessary. A case report and literature review. Int J Surg Case Rep. 2015; №10:179-182.
  26. Afshar et al. Reducing antibiotic use for uncomplicated urinary tract infection in general practice by treatment with uva-ursi (REGATTA) – a double-blind, randomized, controlled comparative effectiveness trial. BMC Complementary and Alternative Medicine 2018; 18:203
  27. European Medicines Agency, Committee on Herbal Medicinal Products (HMPC). Community herbal monograph on Arctostaphylos uva-ursi (L.) Spreng, folium; 2012. p. 1–6.
  28. Chen O, Mah E, Liska D. Effect of Cranberry on Urinary Tract Infection Risk: A Meta- Analyses (P06-116-19). Curr Dev Nutr. 2019 Jun; 3(Suppl 1): nzz031.P06-116-19.
  29. Guet-Revillet H., et al. Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum β-lactamase- producing Enterobacteriaceae: an in silico pharmacokinetic study. Int J Antimicrob Agents. 2017 Jan;49(1):62-66.
  30. Seo et al. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli. BMC Infectious Diseases 2017; 17:404
  31. Sarikaya I., Sarikaya A. Current Status of Radionuclide Renal Cortical Imaging in Pyelonephritis. J Nucl Med Technol 2019; 47:309–312.
  32. Bientinesi R, Murri R, Sacco E. Efficacy, and safety of levofloxacin as a treatment for complicated urinary tract infections and pyelonephritis. Expert Opin Pharmacother. 2020 Apr;21(6):637-644. doi: 10.1080/14656566.2020.1720647.
  33. Dong-Gi Lee, Seung Hyun Jeon, et al. Acute Pyelonephritis: Clinical Characteristics and the Role of the Surgical Treatment. J Korean Med Sci. 2009 Apr; 24(2): 296–301.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*